1-3 of 3
Greg O'Connor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Tammie Yeh, PhD, Greg O'Connor, MS, Justin Cidado, PhD, J. Carl Barrett, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3505.
https://doi.org/10.1182/blood-2018-99-114948
Published: 2018
Journal Articles

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

Kristen A McEachern, PhD, Adriana E Tron, PhD, Greg O'Connor, Rachel DuPont, Francis D Gibbons, PhD, Lourdes Pablo, Karthick Vishwanathan, PhD, Patricia McCoon, PhD, Jorge E. Cortes, MD, Daniel J. DeAngelo, MDPhD, Mark D Minden, MDPhD, Geoffrey L. Uy, MD, Frank Neumann, MDPhD, Karen Keating, Dennis Huszar, PhD, J. Elizabeth Pease, PhD, Jeffrey Brown, PhD, J. Carl Barrett, PhD
Journal: Blood
Blood (2014) 124 (21): 906.
https://doi.org/10.1182/blood.V124.21.906.906
Published: 2014
Journal Articles

Spleen Tyrosine Kinase Inhibitor Fostamatinib Blocks B Cell Receptor Signaling and Reduces Viability of BCR Subtype Diffuse Large B Cell Lymphoma

Yue Zhang, Ph.D., Julie Parmentier, Zhongwu Lai, Ph.D., Greg O'Connor, Melissa Passino, Ph.D., Francoise Powell, Erik Devereaux, Kate Byth, Ph.D.
Journal: Blood
Blood (2012) 120 (21): 3720.
https://doi.org/10.1182/blood.V120.21.3720.3720
Published: 2012